Press Releases BeyondSpring Inc.

Equities

BYSI

KYG108301006

Delayed Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
2.41 ^USD	-1.23%		-13.31%	+167.78%

May. 21	Top Premarket Decliners	MT
May. 15	Transcript : BeyondSpring Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics	May. 16	AQ
BEYONDSPRING TO HOST VIRTUAL R&D DAY TO DISCUSS NEW PLINABULIN DEVELOPMENT STRATEGY FOR CANCER AND UPDATES FOR SEED THERAPEUTICS	May. 06	AQ
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics	May. 03	AQ
BeyondSpring Files 2023 Annual Report on Form 20-F	Apr. 29	AQ
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results	Apr. 29	AQ
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	Mar. 25	AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements	Feb. 26	AQ
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K	Jan. 10	AQ
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements	Dec. 18	AQ
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors	Nov. 07	AQ
BEYONDSPRING AND PROFESSOR K. EISENMANN OF THE UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE PRESENT POSTER HIGHLIGHTING PLINABULIN'S ANTI-CANCER EFFICACY IN PRIMARY AND RECURRENT GLIOBLASTOMA PATIENT DERIVED INVASIVE NEUROSPHERE MODELS	Nov. 01	AQ
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models	23-10-31	AQ
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement	23-10-30	AQ
SEED THERAPEUTICS DISCLOSES NOVEL MOLECULAR GLUE IND CANDIDATE FOR CANCER AT 'TARGETED PROTEIN DEGRADATION THINK TANK' SYMPOSIUM	23-10-27	AQ
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium	23-10-26	AQ
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors	23-10-23	AQ
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements	23-10-04	AQ
BEYONDSPRING AND LEADING CANCER CENTER TO PRESENT POSTER AT SITC'S 38TH ANNUAL MEETING	23-09-28	AQ
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting	23-09-27	AQ
BeyondSpring : Form 20-F T Form 40-F □ - Form 6-K	23-09-20	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BeyondSpring Inc.

Equities

BYSI

KYG108301006

Press Releases

Filters